Why is Recursion Pharma (RXRX) stock up 100% today
Get Alerts RXRX Hot Sheet
Join SI Premium – FREE
Recursion Pharmaceuticals (NASDAQ: RXRX) shares are trading more than 100% higher on Wednesday after the techbio company announced a $50 million investment by Nvidia (NASDAQ: NVDA).
The investment was made as a private investment in public equity (PIPE), according to PR.
“Our collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world’s most difficult challenges, drug discovery,” said Chris Gibson, Ph.D., Co-founder and CEO of Recursion.
“With our powerful dataset and NVIDIA’s accelerated computing capabilities, we intend to create groundbreaking foundation models in biology and chemistry at a scale unlike anything that has ever been released in the biological space.”
The techbio company also said it plans to ramp up the development of its AI foundation models for biology and chemistry in partnership with the chip titan.
"Generative AI is a revolutionary tool to discover new medicines and treatments,” said Jensen Huang, founder and CEO of NVIDIA. “We are delighted to collaborate with Recursion’s world-class team, which is doing pioneering work in digital biology and chemistry with NVIDIA DGX and NVIDIA AI software to accelerate the development of the world’s largest biomolecular generative AI models and speed drug discovery for biotech and pharmaceutical companies.”
RXRX shares are now up 75% year-to-date.
By Senad Karaahmetovic
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- This stock heads into earnings with 'a bag full of cash and a low valuation': analysts
- This digital health stock is ready to re-rate higher: Goldman
- UBS says we are entering a catalyst rich period for this big pharma stock
Create E-mail Alert Related Categories
Corporate News, Hot Corp. News, Hot List, Momentum MoversRelated Entities
Senad KaraahmetovicSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share